VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior m...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2009-03, Vol.11 (2), p.94-101
Main Authors: Cowey, C. Lance, Rathmell, W. Kimryn
Format: Article
Language:English
Subjects:
Biomarkers, Tumor
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Medicine
Medicine & Public Health
Mutation
Oncology
Prognosis
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Von Hippel-Lindau Tumor Suppressor Protein - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene ( VHL ) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-009-0015-5